|
Market Closed -
Nasdaq
01:30:00 24/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 10.84 USD | -2.43% |
|
+11.29% | -30.87% |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 924.8 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | -9.43% | - | - |
| Enterprise Value (EV) 1 | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 607.1 | 493.9 | 239.1 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | -40.54% | -18.65% | -51.58% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -7.41x | -5.82x | -6.55x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | 2.46x | 2.06x | 1.81x |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.2x | 0.6x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 13.5x | 14.3x | 8.66x |
| EV / Revenue | - | - | - | 0.72x | 8.26x | 8.88x | 7.64x | 2.24x |
| EV / EBITDA | -8.53x | -0.97x | -0.37x | -0.74x | - | -4.02x | -4.03x | -1.37x |
| EV / EBIT | -8.28x | -0.94x | -0.35x | -0.67x | -18.8x | -3.62x | -2.33x | -1.17x |
| EV / FCF | -8.74x | -1x | -0.8x | 1.43x | -37.1x | -10.3x | -7.06x | 7.64x |
| FCF Yield | -11.4% | -99.9% | -125% | 70.1% | -2.69% | -9.73% | -14.2% | 13.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.463 | -1.864 | -1.656 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 68.35 | 64.61 | 106.8 |
| EBITDA 1 | -70.75 | -108.6 | -137.1 | -72.99 | - | -151 | -122.4 | -174.9 |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -167.9 | -212.3 | -204.4 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -147.9 | -196.5 | -191.2 |
| Net Debt 1 | -346.1 | -262.8 | -232.4 | -372.1 | - | -317.7 | -430.9 | -685.7 |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 10.84 | 10.84 | 10.84 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 85,313 | - | - |
| Announcement Date | 29/03/22 | 16/03/23 | 14/03/24 | 20/03/25 | 17/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.41x | 8.88x | -4.02x | - | 92Cr | |
| 18.83x | 6.63x | 13.18x | 1.58% | 6.47TCr | |
| 30.16x | 7.93x | 26.43x | 0.05% | 5.48TCr | |
| 36.79x | 6.53x | 19.51x | 0.88% | 5.35TCr | |
| 35.59x | 3.45x | 14.87x | -.--% | 4.6TCr | |
| 49.71x | 5.74x | 31.52x | -.--% | 4.29TCr | |
| -19.41x | 187.75x | -20.66x | -.--% | 4.01TCr | |
| 28.93x | 8.21x | 21.27x | 0.37% | 3.35TCr | |
| 32.66x | 5.97x | 20.09x | -.--% | 2.37TCr | |
| 27.67x | 5.83x | 15.12x | -.--% | 2.4TCr | |
| Average | 23.35x | 24.69x | 13.73x | 0.32% | 3.84TCr | |
| Weighted average by Cap. | 26.64x | 25.28x | 15.89x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
